Literature DB >> 24338371

Ultrasonographic indications for conservative treatment in pregnancy-related uterine arteriovenous malformations.

Tae Young Lee1, See Hyung Kim2, Hee Jung Lee1, Mi Jeong Kim1, Sang Kwon Lee1, Young Hwan Kim1, Seung Hyun Cho3.   

Abstract

BACKGROUND: Uterine arteriovenous malformations (AVMs) are known to spontaneously regress.
PURPOSE: To assess the predictive value of ultrasonography for patients requiring conservative treatment for pregnancy related to AVMs.
MATERIAL AND METHODS: Our prospective study included 75 patients (conservative management:therapeutic management = 45:30) with vaginal bleeding from pregnancy-related AVM. Clinical and ultrasonography examinations were reviewed, and the following information was gathered: complete blood count, AVM maximal diameter, AVM echogenicity, retained product of conception, number of blood vessels, and spectral Doppler (pulsatility index [PI], resistance index [RI], peak systolic velocity [PSV], time-averaged maximum velocity [TAMXV]). The Doppler criteria by Timmerman (mean PSV >70 cm/s: therapeutic management, mean PSV < 52 cm/s: conservative management) were used for the initial management selection. The association between experimental variables and outcomes was assessed to determine their usefulness for predicting conservative management.
RESULTS: Features strongly associated with conservative management and their accuracy were PSV 89.6%, hemoglobin 84.7%, RI 83.1%, TAMXV 79.3%, and PI 78.6%. The overall accuracy for correct outcome classification was 64 (85.3%) of 75 patients. Most patients with conservative management had quicker improvement of symptoms and spontaneous regression at follow-up.
CONCLUSION: Ultrasonography can accurately predict selection of conservative management. © The Foundation Acta Radiologica 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Arteriovenous malformations (AVMs); ultrasonography; uterus

Mesh:

Substances:

Year:  2013        PMID: 24338371     DOI: 10.1177/0284185113514222

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Predictive factors for massive hemorrhage in women with retained products of conception: a prospective study.

Authors:  Reina Sonehara; Tomoko Nakamura; Akira Iwase; Kazuki Nishida; Sachiko Takikawa; Mayuko Murakami; Sayako Yoshita; Ayako Muraoka; Natsuki Miyake; Natsuki Nakanishi; Satoko Osuka; Maki Goto; Hiroaki Kajiyama
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  Retained Placenta Percreta with Acquired Uterine Arteriovenous Malformation-Case Report and Short Review of the Literature.

Authors:  Tudor Butureanu; Raluca Anca Balan; Razvan Socolov; Nicolae Ioanid; Demetra Socolov; Dumitru Gafitanu
Journal:  Diagnostics (Basel)       Date:  2022-04-05

3.  Hysteroscopic Management of Uterine Arteriovenous Malformation.

Authors:  Stefano Calzolari; Mauro Cozzolino; Eleonora Castellacci; Valeria Dubini; Alfonso Farruggia; Giovanni Sisti
Journal:  JSLS       Date:  2017 Apr-Jun       Impact factor: 2.172

Review 4.  Multimodality imaging in secondary postpartum or postabortion hemorrhage: retained products of conception and related conditions.

Authors:  Yuko Iraha; Masahiro Okada; Masafumi Toguchi; Kimei Azama; Keiko Mekaru; Tadatsugu Kinjo; Wataru Kudaka; Yoichi Aoki; Hajime Aoyama; Akiko Matsuzaki; Sadayuki Murayama
Journal:  Jpn J Radiol       Date:  2017-10-19       Impact factor: 2.374

5.  Spontaneous Regression of Uterine Arteriovenous Malformations with Conservative Management.

Authors:  Keiko Mekaru; Sugiko Oishi; Kozue Akamine; Chiaki Heshiki; Yoichi Aoki
Journal:  Case Rep Obstet Gynecol       Date:  2017-02-16

6.  Spontaneous Resolution of an Acquired Uterine Arteriovenous Malformation in an Elderly Primigravida.

Authors:  Viola Ghizzoni; Silvia Gabbrielli; Luca Mannini; Flavia Sorbi; Irene Turrini; Giulia Fantappiè; Dora Pavone; Massimiliano Fambrini; Ivo Noci
Journal:  Am J Case Rep       Date:  2018-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.